home / stock / lixt / lixt news

LIXT News and Press, Lixte Biotechnology Holdings Inc. From 04/28/21

Stock Information
Company Name: Lixte Biotechnology Holdings Inc.
Stock Symbol: LIXT
Market: OTC
Website: lixte.com
Menu
LIXT LIXT Quote LIXT Short LIXT News LIXT Articles LIXT Message Board
Get LIXT Alerts

News, Short Squeeze, Breakout and More Instantly...
LIXT - Lixte Biotechnology to Discuss Pipeline of Clinical Investigations for Four Cancer Targets at the Benzinga Global Small Cap Conference Being Held May 13-14

Lixte’s pipeline includes three clinical studies and one pharmacology study of lead drug candidate LB-100 EAST SETAUKET, NY, April 28, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc . (Nasdaq: LIXT), a clinical-stage drug disc...
LIXT - Lixte Biotechnology Holdings, Inc. Announces the Appointment of Gil N Schwartzberg to its Board of Directors

EAST SETAUKET, New York, April 13, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (“Lixte” or the “Company”) ( Nasdaq: LIXT ), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, anno...

LIXT - Lixte Biotechnology to Present Its Novel Product Candidate for Targeted Cancer Therapy at the Benzinga Biotech Small Cap Conference on March 24

More than 40 preclinical studies have found that Lixte’s lead drug candidate LB-100 increases the anti-tumor activity of chemotherapy, radiotherapy and immunotherapy without increasing toxicity EAST SETAUKET, NY, March 17, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechn...

LIXT - Lixte Biotechnology to Showcase Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual 33rd Annual ROTH Capital Conference

LB-100 is Currently in Clinical Studies for Four Cancer Targets: Phase 1b/2 for Myelodysplastic (MDS) Syndromes Phase 1b/2 for Advanced Soft Tissue Sarcoma Phase 0 (Pharmacodynamics) for Glioblastoma Multiforme Phase 1b for Small Cell Lu...
LIXT - WestPark Capital Announces Completion of $4.19 Million Registered Direct Offering for Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT)

WestPark Capital, Inc., a full-service investment bank and securities broker-dealer, today announced the completion of a Registered Direct Offering for Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs fo...

LIXT - WallachBeth Capital Announces Completion of $4.19 Million Registered Direct Offering for Lixte Biotechnology Holdings, Inc.

WallachBeth Capital Announces Completion of $4.19 Million Registered Direct Offering for Lixte Biotechnology Holdings, Inc. PR Newswire JERSEY CITY, N.J. , March 2, 2021 /PRNewswire/ -- WallachBeth Capital, a leading provider of capital markets and institutional ...

LIXT - Lixte Biotechnology Announces the Closing of $4.19 Million Registered Direct Offering

East Setauket, March 02, 2021 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, today announced that it has closed a registered direct offering with certa...
LIXT - SOS, MNKD, CAN and OTRK among midday movers

Gainers: Morphic (MORF) +106%.Aemetis (AMTX) +58%.SOS (SOS) +43%.Canaan (CAN) +41%.electroCore (ECOR) +37%.Vector Acquisition (VACQU) +37%.The9 (NCTY) +36%.One Stop Systems (OSS) +30%.HCI Group (HCI) +29%.ZK International (ZKIN) +27%.Losers: Athenex (ATNX) -52%.O...

LIXT - Morphic, electroCore leads healthcare gainers; Athenex, Ontrak among major losers

Gainers: Morphic (MORF) +104%, electroCore (ECOR) +51%, Apollo Endosurgery (APEN) +24%, ASLAN Pharmaceuticals (ASLN) +23%, Satsuma Pharmaceuticals (STSA) +19%.Losers: Athenex (ATNX) -51%, Ontrak (OTRK) -48%, CorMedix (...

LIXT - Lixte Biotechnology slumps 18% after raising ~$4.2M

Lixte Biotechnology (LIXT) enters agreement for purchase and sale of 1.3M shares of common stock, at a purchase price of $3.70 per share, in a registered direct offering; gross proceeds $4.19M. Closing expected on or about March 2, 2021.Gross proceeds from the offering are expected ...
Previous 10 Next 10